These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 23151915

  • 1. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [Abstract] [Full Text] [Related]

  • 2. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
    Demirci E, Ocak M, Kabasakal L, Araman A, Ozsoy Y, Kanmaz B.
    Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
    [Abstract] [Full Text] [Related]

  • 3. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ.
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [Abstract] [Full Text] [Related]

  • 4. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.
    Traub-Weidinger T, Putzer D, von Guggenberg E, Dobrozemsky G, Nilica B, Kendler D, Bale R, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1995-2001. PubMed ID: 26173620
    [Abstract] [Full Text] [Related]

  • 5. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
    Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, Warwitz B, Gerardo L, Henninger B, Virgolini I, Rodrigues M.
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
    [Abstract] [Full Text] [Related]

  • 6. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
    Traub-Weidinger T, Von Guggenberg E, Dobrozemsky G, Kendler D, Eisterer W, Bale R, Putzer D, Gabriel M, Virgolini I.
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
    [Abstract] [Full Text] [Related]

  • 7. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours.
    Rodrigues M, Traub-Weidinger T, Li S, Ibi B, Virgolini I.
    Eur J Nucl Med Mol Imaging; 2006 May; 33(5):532-40. PubMed ID: 16491425
    [Abstract] [Full Text] [Related]

  • 8. Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours.
    Gaertner FC, Plum T, Kreppel B, Eppard E, Meisenheimer M, Strunk H, Bundschuh RA, Sinnes JP, Rösch F, Essler M.
    Nucl Med Biol; 2019 May; 76-77():1-9. PubMed ID: 31520872
    [Abstract] [Full Text] [Related]

  • 9. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
    Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ.
    J Nucl Med; 2007 Apr; 48(4):508-18. PubMed ID: 17401086
    [Abstract] [Full Text] [Related]

  • 10. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
    Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, Gabriel M, Kendler D, Waitz D, Widmann G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
    [Abstract] [Full Text] [Related]

  • 11. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
    Sainz-Esteban A, Prasad V, Schuchardt C, Zachert C, Carril JM, Baum RP.
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
    [Abstract] [Full Text] [Related]

  • 12. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B.
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [Abstract] [Full Text] [Related]

  • 13. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.
    Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, Dudczak R, Virgolini I.
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1144-51. PubMed ID: 15909194
    [Abstract] [Full Text] [Related]

  • 14. Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment.
    van de Weijer T, Bemer F, de Vos-Geelen J, Hermans B, Mitea C, van der Pol JAJ, Lodewick T, Wildberger JE, Mottaghy FM.
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2420-2427. PubMed ID: 38403723
    [Abstract] [Full Text] [Related]

  • 15. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B, Asopa R, Basu S.
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [Abstract] [Full Text] [Related]

  • 16. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
    Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, Vonguggenberg E, Warwitz B, Virgolini IJ.
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of [68Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [68Ga]Ga-DOTA-NOC PET/CT.
    Yadav D, Ballal S, Yadav MP, Tripathi M, Roesch F, Bal C.
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796
    [Abstract] [Full Text] [Related]

  • 18. Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?
    Al-Ibraheem A, Bundschuh RA, Notni J, Buck A, Winter A, Wester HJ, Schwaiger M, Scheidhauer K.
    Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):2005-13. PubMed ID: 21792572
    [Abstract] [Full Text] [Related]

  • 19. Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation.
    Aalbersberg EA, de Wit-van der Veen BJ, Versleijen MWJ, Saveur LJ, Valk GD, Tesselaar MET, Stokkel MPM.
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):696-703. PubMed ID: 30097670
    [Abstract] [Full Text] [Related]

  • 20. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
    Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Burggasser G, Andreae F, Kurtaran A, Dudczak R.
    Curr Pharm Des; 2002 Mar; 8(20):1781-807. PubMed ID: 12171531
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.